Amgen's Q2 Revenue Hits $9.2B as Top-Volume Stock Strategy Surpasses Market Gains by 137%

Amgen’s shares rose 1.24% on August 8, with a trading volume of $0.52 billion, a 29.73% decline from the previous day’s activity. The biopharma giant reported robust second-quarter performance, driven by strong sales growth in key therapeutic areas and product categories.

Revenues totaled $9.2 billion, up 9% year-over-year, with product sales reaching $8.77 billion. Repatha and Evenity were standout performers, generating $696 million and $518 million respectively, both surging over 30% year-over-year. The growth was fueled by volume expansion, particularly in the U.S., despite pricing pressures from rebates and deductions. Rare disease drugs contributed $1.4 billion in sales, a 19% increase, with Tepezza, Krystexxa, and Uplizna showing double-digit growth. Oncology sales also rose 14%, led by Blincyto’s 45% year-over-year jump to $384 million.

Biosimilars added $661 million in the quarter, a 40% annual increase, though older products faced erosion from competition. New launches like Wezlana (Stelara biosimilar) and Pavblu (Eylea biosimilar) began contributing to revenue. However, legacy products like Enbrel declined 34% due to pricing pressures and market share losses. Amgen raised its 2025 revenue forecast to $35–$36 billion, citing momentum in key drugs and biosimilars, though patent expirations for Prolia and Xgeva in late 2025 may temper growth in the latter half of the year.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.